Chen Chen

Chen’s experience includes representing:

• Merus in its research collaboration with Biohaven to co-develop three novel bispecific antibody-drug conjugates (ADCs), leveraging Merus’ leading antibody technology platform and Biohaven’s ADC conjugation and payload platform technologies*
• Avenzo Therapeutics in its agreement with Duality Biotherapeutics to obtain global rights (excluding Greater China) for DB-1418, an epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 3 (HER3) bispecific ADC*
• Kura Oncology in its global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, Kura’s selective oral menin inhibitor, with profit-sharing in the US*
• Radionetics Oncology in its strategic collaboration with Eli Lilly to develop Radionetics’ proprietary G protein-coupled receptor-targeting small molecule radiopharmaceuticals, with an option for Lilly to acquire Radionetics upon conclusion of an exercise period*
• SystImmune in its global collaboration with Bristol Myers Squibb (BMS) to develop and commercialize BL-B01D1, SystImmune’s novel EGFR/HER3 bispecific ADC, with profit-sharing in the US*
• MediLink Therapeutics in its strategic collaboration with BioNTech to license MediLink’s proprietary ADC directed to HER3, with MediLink retaining rights in Greater China*
• Genomatica in its joint venture with Unilever to commercialize and scale plant-based alternatives to feedstocks like palm oil and fossil fuels to make key ingredients used in everyday cleaning and personal care products*
• Arsenal Biosciences in its multi-year, multi-program discovery collaboration with BMS to advance next-generation T-cell therapies to treat solid tumors
• Vir Biotechnology in its multi-program collaboration with GlaxoSmithKline (GSK) to develop and commercialize therapies for coronaviruses, including antibody, vaccine, and functional genomics programs*

*Matter handled prior to joining Latham